Combined nano cancer immunotherapy based on immune status in a tumor microenvironment

Nakamura, Takashi; Kawakami, Kimihiro; Nomura, Momoka; Sato, Yusuke; Hyodo, Mamoru; Hatakeyama, Hiroto; Hayakawa, Yoshihiro; Harashima, Hideyoshi

doi:10.1016/j.jconrel.2022.03.026

Cited by 17 publications

(8 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It explains for the first time why activation of STING can enhance the expression of PD-L1 in tumor cells. This conclusion is consistent with the claim that the antitumor activity of tumor immunotherapy can be assessed by the immune status in the TME ( 40 ). Furthermore, their research group also paid close attention to the importance of the treatment protocol setting of the combined application of SING-LNP and PD-1 antibody, such as the number of cycles of administration, and the order and interval between therapy administration ( 41 ).…”

Section: Nanomedicine Targeting Activation Of Sting In the Cancer Imm...supporting

confidence: 92%

Nanomedicines targeting activation of STING to reshape tumor immune microenvironment and enhance immunotherapeutic efficacy

et al. 2023

View full text Add to dashboard Cite

Immunotherapy has greatly enhanced the effectiveness of cancer treatments, but the efficacy of many current immunotherapies is still limited by the tumor-suppressive immune microenvironment. Multiple studies have shown that activating the stimulation of IFN genes (STING) pathway and inducing innate immunity can significantly impact the tumor immune microenvironment and improve antitumor therapy. While natural or synthetic STING agonists have been identified or developed for preclinical and clinical use, small molecule agonists have limited utility due to degradation and lack of targeting. As such, the delivery and release of STING agonists into tumor tissue is a major challenge that must be addressed in order to further advance the use of STING agonists. To address this challenge, various nanomedicines have been developed. In this paper, we concisely review the antitumor immunotherapeutic mechanisms of STING agonists, highlighting the latest developments in STING agonists and the current progress of nanomedicines for activating STING. We classify the different nanomedicines according to the STING agonists they utilize in order to facilitate understanding of recent advances in this field. Finally, we also discuss the prospects and challenges of this field.

show abstract

Section: Nanomedicine Targeting Activation Of Sting In the Cancer Imm...supporting

confidence: 92%

Nanomedicines targeting activation of STING to reshape tumor immune microenvironment and enhance immunotherapeutic efficacy

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Results exhibited an improved survival rate in mice compared to control groups and the only-treated-with-PTX group [ 208 ]. Lipid nanocapsules (LNCs) with a size of 100 nm efficiently target myeloid-derived suppressor cells (MDSCs) isolated from GB patients and induced their inhibition [ 209 ]. To notice the clinical significance of NPs is still to be discovered, but their therapeutic potential is promising.…”

Section: Other Therapeutic Approaches In Gbmentioning

confidence: 99%

Recent Developments in Glioblastoma Therapy: Oncolytic Viruses and Emerging Future Strategies

Hamad

Yusubalieva

Baklaushev

et al. 2023

Viruses

View full text Add to dashboard Cite

Glioblastoma is the most aggressive form of malignant brain tumor. Standard treatment protocols and traditional immunotherapy are poorly effective as they do not significantly increase the long-term survival of glioblastoma patients. Oncolytic viruses (OVs) may be an effective alternative approach. Combining OVs with some modern treatment options may also provide significant benefits for glioblastoma patients. Here we review virotherapy for glioblastomas and describe several OVs and their combination with other therapies. The personalized use of OVs and their combination with other treatment options would become a significant area of research aiming to develop the most effective treatment regimens for glioblastomas.

show abstract

“…Apart from repolarizing the macrophages from the M2 to M1 phenotype, graphdiyne was found to modulate the MAPK and TLR signalling pathways along with inlterleukin-1 processing, thereby activating T cells in a partially STAT3 independent route. A recent study had focussed on understanding the cancer genes that determine the responsiveness or resistance of the cancer cells towards PD-L1 inhibitors [ 162 ]. A panel of 10 genes were identified across different types of cancers that were then used to screen various therapeutic agents and nanoparticles.…”

Section: Recent Developments In Cancer Immunotherapymentioning

confidence: 99%

Emerging Trends in Nano-Driven Immunotherapy for Treatment of Cancer

2023

View full text Add to dashboard Cite

Despite advancements in the development of anticancer medications and therapies, cancer still has the greatest fatality rate due to a dismal prognosis. Traditional cancer therapies include chemotherapy, radiotherapy, and targeted therapy. The conventional treatments have a number of shortcomings, such as a lack of selectivity, non-specific cytotoxicity, suboptimal drug delivery to tumour locations, and multi-drug resistance, which results in a less potent/ineffective therapeutic outcome. Cancer immunotherapy is an emerging and promising strategy to elicit a pronounced immune response against cancer. Immunotherapy stimulates the immune system with cancer-specific antigens or immune checkpoint inhibitors to overcome the immune suppressive tumour microenvironment and kill the cancer cells. However, delivery of the antigen or immune checkpoint inhibitors and activation of the immune response need to circumvent the issues pertaining to short lifetimes and effect times, as well as adverse effects associated with off-targeting, suboptimal, or hyperactivation of the immune system. Additional challenges posed by the tumour suppressive microenvironment are less tumour immunogenicity and the inhibition of effector T cells. The evolution of nanotechnology in recent years has paved the way for improving treatment efficacy by facilitating site-specific and sustained delivery of the therapeutic moiety to elicit a robust immune response. The amenability of nanoparticles towards surface functionalization and tuneable physicochemical properties, size, shape, and surfaces charge have been successfully harnessed for immunotherapy, as well as combination therapy, against cancer. In this review, we have summarized the recent advancements made in choosing different nanomaterial combinations and their modifications made to enable their interaction with different molecular and cellular targets for efficient immunotherapy. This review also highlights recent trends in immunotherapy strategies to be used independently, as well as in combination, for the destruction of cancer cells, as well as prevent metastasis and recurrence.

show abstract

Combined nano cancer immunotherapy based on immune status in a tumor microenvironment

Cited by 17 publications

References 60 publications

Nanomedicines targeting activation of STING to reshape tumor immune microenvironment and enhance immunotherapeutic efficacy

Nanomedicines targeting activation of STING to reshape tumor immune microenvironment and enhance immunotherapeutic efficacy

Recent Developments in Glioblastoma Therapy: Oncolytic Viruses and Emerging Future Strategies

Emerging Trends in Nano-Driven Immunotherapy for Treatment of Cancer

Contact Info

Product

Resources

About